Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment

Frontiers in Oncology

Volumn 4 JUN, Issue , 2014, Pages

  Renovanz, Mirjam ^a   Kim, Ella L ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Anti cancer therapy; Cancer; Intratumor heterogeneity; Tumor recurrence

Indexed keywords

CYTOTOXIC AGENT;

ADVANCED CANCER; ARTICLE; AUTOPHAGY; CANCER GROWTH; CANCER STEM CELL; CANCER THERAPY; CARCINOGENICITY; CELL CLONE; CELL DEATH; CELL HETEROGENEITY; CELL PROLIFERATION; CYTOTOXICITY; DNA REPAIR; DRUG METABOLISM; DRUG POTENTIATION; FEEDBACK SYSTEM; GENE EXPRESSION; GENE TARGETING; GENETIC VARIABILITY; GENOMICS; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; INTRATUMOR HETEROGENEITY; MONOTHERAPY; MUTATION; NEOPLASM; ONCOGENE; TUMOR RECURRENCE; TUMOR RESISTANCE; UNFOLDED PROTEIN RESPONSE;

EID: 84904656411     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00142     Document Type: Article

References (34)

1. Adams JM, Kelly PN, Dakic A, Carotta S, Nutt SL, Strasser A. Role of "cancer stem cells" and cell survival in tumor development and maintenance. Cold Spring Harb Symp Quant Biol (2008) 73:451-9. doi: 10.1101/sqb.2008.73.004
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
3. Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell (2012) 23:1-6. doi:10.1091/mbc.E10-04-0335
4. Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, et al. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis (2013) 34:725-38. doi:10.1093/carcin/bgt086
5. Kastan MB. DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes memorial award lecture. Mol Cancer Res (2008) 6:517-24. doi:10.1158/1541-7786.MCR-08-0020
6. Bernards R. A missing link in genotype-directed cancer therapy. Cell (2012) 151:465-8. doi:10.1016/j.cell.2012.10.014
7. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science (2013) 339:1546-58. doi:10.1126/science.1235122
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 364:2507-16. doi:10.1056/NEJMoa1103782
9. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 348:994-1004. doi:10.1056/NEJMoa022457
10. Blair BG, Bardelli A, Park BH. Somatic alterations as the basis for resistance to targeted therapies. J Pathol (2014) 232:244-54. doi:10.1002/path.4278
11. Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev (2012) 26:641-50. doi:10.1101/gad.186965.112
12. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 483:100-3. doi:10.1038/nature10868
13. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2013) 19:657-67. doi:10.1158/1078-0432.CCR-11-1446
14. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 451:1116-20. doi:10.1038/nature06633
15. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature (2009) 458:719-24. doi:10.1038/nature07943
16. Mardis ER. Genome sequencing and cancer. Curr Opin Genet Dev (2012) 22:245-50. doi:10.1016/j.gde.2012.03.005
17. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature (2013) 501:328-37. doi:10.1038/nature12624
18. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 4:127s110. doi:10.1126/scitranslmed.3003854
19. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 121:3810-8. doi:10.1172/JCI57088
20. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 366:883-92. doi:10.1056/NEJMoa1113205
21. Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell RA, Rowan AJ, et al. Parallel evolution of tumour subclones mimics diversity between tumours. J Pathol (2013) 230:356-64. doi:10.1002/path.4214
22. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 110:4009-14. doi:10.1073/pnas.1219747110
23. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 501:338-45. doi:10.1038/nature12625
24. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 30:413-21. doi:10.1038/nbt.2203
25. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 144:27-40. doi:10.1016/j.cell.2010.11.055
26. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 17:98-110. doi:10.1016/j.ccr.2009.12.020
27. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 17:362-75. doi:10.1016/j.ccr.2009.12.049
28. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 8:755-68. doi:10.1038/nrc2499
29. Garvalov BK, Acker T. Cancer stem cells: a new framework for the design of tumor therapies. J Mol Med (Berl) (2011) 89:95-107. doi:10.1007/s00109-010-0685-3
30. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 21:283-96. doi:10.1016/j.ccr.2012.03.003
31. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 481:506-10. doi:10.1038/nature10738
32. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 120:1067-76. doi:10.1182/blood-2012-01-405985
33. Sia Y, Field K, Rosenthal M, Drummond K. Socio-demographic factors and their impact on the number of resections for patients with recurrent glioblastoma. J Clin Neurosci (2013) 20:1362-5. doi:10.1016/j.jocn.2013.02.010
34. Jones SJ, Laskin J, Li YY, Griffith OL, An J, Bilenky M, et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol (2010) 11:R82. doi:10.1186/gb-2010-11-8-r82